Clinical trials: Tumor Immune Microenvironment
Colon Cancer
OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
This is a prospective, double-blind, placebo-controlled, randomized clinical trial to assess the effects of daily 4-gram marine omega-3 polyunsaturated fatty acid (MO3PUFA), through treatment with AMR101 (VASCEPA, icosapent…
- Trial name
- OMICC (NCT03661047)
- Testing
- AMR101 (VASCEPA, icosapent ethyl)
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer
COLON-IM : Microbiota and Immune Infiltrate in Normal, Dysplastic and Neoplastic Colorectal Tissue
The primary objective of COLON-IM is to describe colorectal tissue microenvironment (neutrophils infiltrate) of patients with benign or malignant colorectal lesion (from stage I to III according to Tumor Node Metastasis (TNM)/…
- Trial name
- NCT03841799
- Where
- 3 sites in France
- Volunteers
- 400 people
- Sponsor
- Centre Leon Berard
Leukemia, Chronic Lymphocytic, Richter Syndrome
Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
This correlative study aims to understand the pharmacodynamic effects and clonal dynamics in response to epcoritamab by obtaining and analyzing lymph node, bone marrow, and blood samples from subjects enrolled in GCT3013-03 trial…
- Trial name
- NCT06676033
- Testing
- epcoritamab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hepatocellular Carcinoma (HCC), Treatment Response
Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
This study aims to explore whether adding an additional MRI sequence to routine liver scans can better characterize the immune microenvironment of liver cancer.
- Trial name
- NCT07838415
- Testing
- time-dependent diffusion MRI and Cest sequence
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tongji Hospital
Endometrium Cancer, Tumor Infiltration
Tumor-Infiltrating Lymphocytes in Endometrial Cancer
Endometrial cancer (EC) is a leading cancer among women globally. The tumor microenvironment in EC is characterized by complex interactions between cancer cells and immune components.
- Trial name
- NCT06976333
- Testing
- Tumor-infliltrating lymphocyte (TIL) percentage, Grey level co-occurrence matrix (GLCM), Fractal dimension (FD)
- Where
- Poland
- Volunteers
- 52 people
- Sponsor
- Jagiellonian University
Nonmelanoma Skin Cancer, Basal Cell Carcinoma
Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)
This research study is for people who have been diagnosed with a nonmelanoma skin cancer (either basal cell carcinoma or squamous cell carcinoma) and are planning to receive either Mohs surgery or ED\&C (electrodessication \&…
- Conditions
- Nonmelanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- NCT07241585
- Testing
- Vitamin D (VitD), Photodynamic therapy (PDT), Mohs surgery or electrodessication & curettage (ED&C) (standard of care)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Case Comprehensive Cancer Center
Invasive Breast Cancer
Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer
This is a prospective, single-center, non-randomized, non-controlled study
- Trial name
- NCT05767931
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University
Breast Neoplasms
Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer
The aim of this prospective, randomized, multicenter, open-label, explorative phase II study is to identify the impact of (neo)adjuvant denosumab on the systemic immunity and local immunologic microenvironment in postmenopausal…
- Trial name
- PERIDENO (NCT03532087)
- Testing
- Denosumab 120 mg, Denosumab 60 mg
- Where
- 8 sites in Netherlands
- Sponsor
- Borstkanker Onderzoek Groep
Melanoma
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
Melanoma in-transit metastases (ITMs) continue to represent a therapeutic dilemma, in that no standard method of treatment has been uniformly adopted.
- Trial name
- NCT04658303
- Testing
- Pimonidazole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yana Najjar
Lung Cancer, Malignancy
Immune- and Microenvironment- Proteogenomics Profiling for Classifying Lung Cancer Patients
The excessive accumulation of fluid between the membranes surrounding the lung, a clinical condition commonly referred to as "pleural effusion", is caused by one of three factors: increased production of pleural fluid, decreased…
- Trial name
- NCT04887545
- Testing
- Proteomics analysis of pleural effusion
- Where
- Portugal
- Volunteers
- 200 people
- Sponsor
- Universidade Nova de Lisboa
Nasopharyngeal Carcinoma (NPC)
Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma
To analyze the spatiotemporal dynamic evolution of nasopharyngeal carcinoma before and after immunotherapy and during tumor progression, 2~3 key cell subsets or node molecules were screened to predict the curative effect.
- Trial name
- NCT07198802
- Testing
- No Intervention
- Volunteers
- 600 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Relapsed Non-Hodgkin Lymphoma
Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research
The T cell characteristics of 12 patients treated with CD20 CAR-T (LY007 cell injection) were analyzed to study their relationship with CAR-T anti-tumor activity, tumor killing, and in vivo proliferation, and to explore the…
- Trial name
- NCT06049381
- Volunteers
- 22 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma
Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment
Immunotherapy with chimeric antigen receptor T-cells (CAR-T) has revolutionized the treatment of oncohematological diseases and its applications in solid tumors and non-neoplastic diseases are advancing.
- Trial name
- NCT06439173
- Testing
- CAR-T cell therapy
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca